(Q36310235)

English

Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders (English)

1 reference

Europe PubMed Central

13 August 2017

2

object named as

Rainer Storb

1 reference

Europe PubMed Central

13 August 2017

author name string

Frédéric Baron

1

1 reference

Europe PubMed Central

13 August 2017

publication date

8 November 2005

1 reference

Europe PubMed Central

13 August 2017

Molecular Therapy

1 reference

Europe PubMed Central

13 August 2017

13

1 reference

Europe PubMed Central

13 August 2017

26-41

1 reference

Europe PubMed Central

13 August 2017

1

1 reference

Europe PubMed Central

13 August 2017

Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Graft-versus-leukemia reactions in allogeneic chimeras

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

The role of allogeneic transplantation in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Transplantation of X-linked severe combined immunodeficient dogs with CD34+ bone marrow cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

What role is there for antithymocyte globulin in allogeneic nonmyeloablative canine hematopoietic cell transplantation?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

What role for FTY720, a novel immunosuppressive agent, in canine nonmyeloablative hematopoietic stem cell transplantation?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Mixed chimerism: preclinical studies and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Mixed bone marrow chimerism as a treatment for autoimmune diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Severe canine hereditary hemolytic anemia treated by nonmyeloablative marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Specific suppressor cells in graft-host tolerance of HLA-identical marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Graft-versus-host disease: how to translate new insights into new therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Stem cell gene transfer--efficacy and safety in large animal studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Stem cell transplantation for congenital immunodeficiencies using reduced-intensity conditioning

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Molecules and mechanisms of the graft-versus-leukaemia effect

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Genetic modification of T lymphocytes for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.09.011

7 January 2021

Identifiers

10.1016/J.YMTHE.2005.09.011

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36310235&oldid=1625172169"